FLT3 and acute myeloid leukemia: It was also shown that the new BTK inhibitor, abivertinib (AC0010), inhibits cell proliferation and reduces the colony forming capacity of AML cells, especially harboring FLT3-ITD mutation, by BTK-dependent and independent mechanisms [39].